MCK - NYSE
McKesson Corporation
$739.53
+0.64%McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
At a Glance
Live SnapshotMcKesson Corporation Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Efficient profit conversion: Minimal margin compression from gross to net indicates lean operations and favorable tax/interest environment.
McKesson Corporation Income Statement
MCK • NYSE
| McKesson Corporation Income Statement | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
403.4B | 359.1B | 309B | 276.7B | 264B | 238.2B | 231.1B | 214.3B | 208.4B | 198.5B | 190.9B | 179B | 137.6B | 122.5B | 122.7B | 112.1B | 108.7B | 106.6B | 101.7B | 93B | |
GROSS PROFIT | ||||||||||||||||||||
(388.9B) | (346.6B) | (296.7B) | (264.8B) | (251.3B) | (226.6B) | (219.7B) | (203.6B) | (198B) | (187.8B) | (179.9B) | (168.1B) | (129.6B) | (115.7B) | (116.3B) | (106.1B) | (103B) | (101.2B) | (96.7B) | (88.6B) | |
14.6B | 12.5B | 12.2B | 11.9B | 12.6B | 11.6B | 11.4B | 10.8B | 10.4B | 10.7B | 10.9B | 10.9B | 8B | 6.8B | 6.4B | 6B | 5.7B | 5.4B | 5B | 4.3B | |
OPERATING INCOME | ||||||||||||||||||||
-8.1B | (8.1B) | (8.3B) | (7.4B) | (9.9B) | (8.1B) | (8.4B) | (7.7B) | (7.5B) | (7.3B) | (7.1B) | (7.4B) | (5.4B) | (4.3B) | (4B) | (3.9B) | (3.7B) | (3.7B) | (3.5B) | (3.1B) | |
-8.1B | (8B) | (8.2B) | (7.3B) | (9.9B) | (8B) | (8.3B) | (7.6B) | (7.3B) | (7B) | (6.7B) | (7B) | (4.9B) | (3.9B) | (3.6B) | (3.5B) | (3.3B) | (3.3B) | (3.2B) | (2.8B) | |
(0.0) | (91M) | (77M) | (89M) | (70M) | (74M) | (96M) | (71M) | (125M) | (341M) | (392M) | (392M) | (456M) | (480M) | (440M) | (407M) | (376M) | (364M) | (347M) | (284M) | |
6.2B | 4.4B | 3.9B | 4.5B | 2.7B | 3.5B | 3B | 3.1B | 2.9B | 3.4B | 3.9B | 3.5B | 2.7B | 2.4B | 2.4B | 2.1B | 2B | 1.7B | 1.5B | 1.3B | |
PRE-TAX INCOME | ||||||||||||||||||||
-247M | (256M) | (243M) | (248M) | (178M) | (217M) | (249M) | (264M) | (283M) | (308M) | (353M) | (374M) | (257M) | (229M) | (251M) | (197M) | (187M) | (144M) | (142M) | (99M) | |
0.0 | -83M | -125M | -141M | -168M | -205M | -200M | -225M | -235M | -279M | -335M | -354M | -234M | -207M | -232M | -179M | -171M | -113M | -53M | 4M | |
-11M | -13M | -138M | 177M | -795M | -8.5B | -1.9B | -2.5B | -2.7B | 3.5B | -601M | -874M | -554M | -501M | -461M | -463M | -146M | -658M | -21M | 13M | |
6.2B | 4.4B | 3.8B | 4.6B | 1.9B | -5B | 1.1B | 610M | 239M | 6.9B | 3.3B | 2.7B | 2.1B | 1.9B | 1.9B | 1.6B | 1.9B | 1.1B | 1.5B | 1.3B | |
NET INCOME | ||||||||||||||||||||
-1.1B | (878M) | (629M) | (905M) | (636M) | -695M | (18M) | (356M) | -53M | (1.6B) | (908M) | (815M) | (742M) | (581M) | (516M) | (505M) | (601M) | (241M) | (468M) | (329M) | |
4.8B | 3.3B | 3B | 3.6B | 1.1B | -4.5B | 900M | 34M | 67M | 5.2B | 2.3B | 1.5B | 1.3B | 1.3B | 1.4B | 1.1B | 1.3B | 823M | 990M | 963M |
SEC Filings
MCK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2026 FY FY | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 03, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 04, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Related Guides
Continue your MCK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.